Safety of direct oral anticoagulants in patients with advanced liver disease.

导出 OA

翻译打印收藏纠错

第一作者： Georg,Semmler

第一单位： Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.

作者： Georg,Semmler ^[1] ; Katharina,Pomej ^[2] ; David J M,Bauer ^[1] ; Lorenz,Balcar ^[2] ; Benedikt,Simbrunner ^[1] ; Teresa,Binter ^[2] ; Lukas,Hartl ^[1] ; Jeannette,Becker ^[2] ; Matthias,Pinter ^[1] ; Peter,Quehenberger ^[2] ; Michael,Trauner ^[3] ; Mattias,Mandorfer ^[1] ; Ton,Lisman ^[2] ; Thomas,Reiberger ^[1] ; Bernhard,Scheiner ^[2]

作者单位： Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria. ^[1] Vienna Hepatic Hemodynamic Lab, Medical University of Vienna, Vienna, Austria. ^[2] Christian Doppler Laboratory for Portal Hypertension and Liver Fibrosis, Medical University of Vienna, Vienna, Austria. ^[3] Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria. ^[4] Surgical Research Laboratory and Section of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. ^[5]

关键词 ACLD DOAC NOAC bleeding edoxaban vascular liver disease

主题词投药, 口服(Administration, Oral);抗凝药(Anticoagulants);肝素, 低分子量(Heparin, Low-Molecular-Weight);人类(Humans);肝疾病(Liver Diseases);回顾性研究(Retrospective Studies);维生素K(Vitamin K)

DOI 10.1111/liv.14992

PMID 34152697

发布时间 2021-09-29

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交